

# Benjamin C Calhoun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/720362/publications.pdf>

Version: 2024-02-01

52  
papers

1,011  
citations

430874

18  
h-index

454955

30  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1638  
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast tissue, oral and urinary microbiomes in breast cancer. <i>Oncotarget</i> , 2017, 8, 88122-88138.	1.8	134
2	Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. <i>Nature Communications</i> , 2019, 10, 3668.	12.8	103
3	Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. <i>Nature Communications</i> , 2018, 9, 578.	12.8	60
4	Predictive factors on outcomes in metaplastic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 499-504.	2.5	58
5	Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies. <i>Modern Pathology</i> , 2015, 28, 670-676.	5.5	47
6	Predictive markers in breast cancer: An update on ER and HER2 testing and reporting. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 362-369.	1.5	47
7	Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature. <i>Histopathology</i> , 2016, 68, 138-151.	2.9	46
8	Core Needle Biopsy of the Breast. <i>Surgical Pathology Clinics</i> , 2018, 11, 1-16.	1.7	37
9	Cystic neutrophilic granulomatous mastitis: The Cleveland Clinic experience with diagnosis and management. <i>Breast Journal</i> , 2019, 25, 80-85.	1.0	36
10	Topical platelet growth factor therapy: of lotions and potions. <i>Transfusion</i> , 2001, 41, 1186-1189.	1.6	34
11	Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of <i>HER2</i> gene amplification in breast cancer. <i>Cancer</i> , 2017, 123, 2230-2239.	4.1	28
12	Genomic Structure of Murine Rab11 Family Members. <i>Biochemical and Biophysical Research Communications</i> , 2000, 269, 611-617.	2.1	27
13	Radial scars diagnosed on breast core biopsy: Frequency of atypia and carcinoma on excision and implications for management. <i>Breast</i> , 2016, 30, 201-207.	2.2	26
14	Joint region and nucleus segmentation for characterization of tumor infiltrating lymphocytes in breast cancer. , 2019, 10956, .		26
15	Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy. <i>Cancer</i> , 2018, 124, 459-465.	4.1	25
16	Atypical apocrine adenosis diagnosed on breast core biopsy: implications for management. <i>Human Pathology</i> , 2014, 45, 2130-2135.	2.0	24
17	A somatodendritic distribution of Rab11 in rabbit brain neurons. <i>NeuroReport</i> , 1996, 7, 1297-1300.	1.2	22
18	Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 189-193.	2.5	21

#	ARTICLE	IF	CITATIONS
19	Sampling Error in the Standard Evaluation of Endoscopic Colonic Biopsies. American Journal of Surgical Pathology, 2003, 27, 254-257.	3.7	19
20	Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women. Journal of the National Cancer Institute, 2020, 112, 728-736.	6.3	19
21	Mucocele-like lesions diagnosed on breast core biopsy: Low risk of upgrade and subsequent carcinoma. Breast Journal, 2018, 24, 314-318.	1.0	18
22	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. JNCI Cancer Spectrum, 2021, 5, pkaa072.	2.9	14
23	Lobular neoplasia diagnosed on breast Core biopsy: frequency of carcinoma on excision and implications for management. Annals of Diagnostic Pathology, 2016, 25, 20-25.	1.3	10
24	Lipomatous tumors of the breast: A contemporary review. Seminars in Diagnostic Pathology, 2017, 34, 453-461.	1.5	10
25	MRI-guided core needle biopsy of the breast: Radiology-pathology correlation and impact on clinical management. Annals of Diagnostic Pathology, 2020, 48, 151563.	1.3	10
26	Breast Cancer Risk Associated With Benign Intraductal Papillomas Initially Diagnosed on Core Needle Biopsy. Clinical Breast Cancer, 2018, 18, 468-473.	2.4	9
27	Protein-based immune profiles of basal-like vs. luminal breast cancers. Laboratory Investigation, 2021, 101, 785-793.	3.7	9
28	The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	8
29	Endosalpingiosis of Axillary Lymph Nodes: A Rare Histopathologic Pitfall with Clinical Relevance for Breast Cancer Staging. Case Reports in Pathology, 2016, 2016, 1-5.	0.3	7
30	The landscape of immune microenvironments in racially-diverse breast cancer patients. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	2.5	7
31	High-risk and selected benign breast lesions diagnosed on core needle biopsy: Evidence for and against immediate surgical excision. Modern Pathology, 2022, 35, 1500-1508.	5.5	7
32	Mitigating Overdiagnosis and Overtreatment in Breast Cancer: What Is the Role of the Pathologist?. Archives of Pathology and Laboratory Medicine, 2014, 138, 1428-1431.	2.5	6
33	HER2 FISH concordance in breast cancer patients with both cytology and surgical pathology specimens. Journal of the American Society of Cytopathology, 2018, 7, 31-36.	0.5	6
34	Clinical and Financial Implications of Second-Opinion Surgical Pathology Review. American Journal of Clinical Pathology, 2021, 156, 559-568.	0.7	6
35	Breast cancer detection in axillary sentinel lymph nodes: the impact of the method of pathologic examination. Human Pathology, 2014, 45, 2497-2501.	2.0	5
36	Calciphylaxis of the Postmenopausal Female Breast: An Uncommonly Encountered Mimic of Carcinoma. Case Reports in Pathology, 2017, 2017, 1-5.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Analytical and clinical performance of progesterone receptor antibodies in breast cancer. <i>Annals of Diagnostic Pathology</i> , 2018, 35, 21-26.	1.3	5
38	Benign, High-Risk, and Premalignant Lesions of the Breast. , 2018, , 116-129.e3.		5
39	Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and <i>HER2</i> Amplification. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342097638.	1.1	5
40	MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy. <i>BMC Cancer</i> , 2016, 16, 695.	2.6	4
41	Ductal Carcinoma In Situ Simultaneously Involving the Breast and Epithelial Inclusions in an Ipsilateral Axillary Lymph Node. <i>International Journal of Surgical Pathology</i> , 2018, 26, 564-568.	0.8	4
42	Quantitative analysis of breast cancer tissue composition and associations with tumor subtype. <i>Human Pathology</i> , 2022, 123, 84-92.	2.0	4
43	Vascular density of histologically benign breast tissue from women with breast cancer: associations with tissue composition and tumor characteristics. <i>Human Pathology</i> , 2019, 91, 43-51.	2.0	3
44	Comparison of immunohistochemistry (IHC) and quantitative RT-PCR: ER, PR, and HER2 receptor status.. <i>Journal of Clinical Oncology</i> , 2012, 30, 47-47.	1.6	2
45	Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab [TCH-P] in non-metastatic HER2+ breast cancer: The Cleveland Clinic experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 531-531.	1.6	2
46	Management of High-Risk Breast Lesions: Pointâ€”Surveillance Is a Change in Practice Preceding Evidence-Based Standardization. <i>American Journal of Roentgenology</i> , 2021, 216, 1432-1433.	2.2	1
47	Breast Mass in a Woman with Recurrent Thymoma. <i>Annals of the American Thoracic Society</i> , 2016, 13, 2097-2098.	3.2	0
48	Triple-Negative/Basal-Like Breast Carcinomas. , 2016, , 431-443.		0
49	Trichogranulomatous mastopathy: Unique pathology in a case of clinical periductal mastitis. <i>Breast Journal</i> , 2020, 26, 524-525.	1.0	0
50	Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes. <i>Annals of Diagnostic Pathology</i> , 2020, 48, 151576.	1.3	0
51	Abstract P4-15-07: HER2 positive (HER2/CEP17 ratioâ‰¥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy. , 2015, , .		0
52	Risk-Associated Lesions of the Breast in Core Needle Biopsies. <i>Surgical Pathology Clinics</i> , 2022, 15, 147-157.	1.7	0